NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization396.83 mln
Float67.25 mln
Earnings Date11/05/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
14.30
Transformational upside
Relative Strength
12
/ 100
Significantly lagging
Debt / Equity
0.04
Debt-free
ROE
-139
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Larimar Therapeutics is a Pennsylvania-based biotech company working to bring new medicines to people with rare and life-threatening conditions. The company has developed a unique technology that allows treatment compounds to enter cells more effectively. Its most advanced drug candidate, CTI-1601, is currently being tested in a Phase 2 clinical trial for Friedreich's ataxia, a rare and progressive disease with no approved cure.
